Looking for the Next Targeted Oncology Blockbuster

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Big Pharma and investors are closely watching the precision oncology space. From 2015 through 2019, targeted oncology companies have appreciated more than 200% compared to a 20% rise in the S&P500. A number of targeted oncology companies continue to break new ground advancing drugs that key in on tumor mutations linked to disease progression. Listen to today’s precision oncology leaders discuss the factors driving success in the lucrative field, and their own approaches to target genetic drivers of cancer.
Moderator
photo
Columnist
Wall Street Journal
Speakers
photo
President, Chief Executive Officer and Board Member
ORIC Pharmaceuticals
photo
Columnist
Wall Street Journal
photo
CEO, President and Director
Boundless Bio Inc.
photo
Chief Medical Officer
QED Therapeutics / BridgeBio
photo
President and Chief Executive Officer
Kura Oncology